MDU sponsoring HF & Usability summit next week

31st January 2017

Medical Device Usability is delighted to be sponsoring the second Human Factors Engineering and Usability Studies summit in Burlingame, California on 7 and 8 February 2017. The two-day conference will feature a range of speakers from companies such as Abbvie, Novartis and Amgen. Medical Device Usability’s, Richard Featherstone, will be speaking on Day One at […]

High Risk Medical Device Study

30th January 2017

MDU have been working extensively over the Christmas and New Year period with a multi-billion $ company to carry out a Summative study on a device considered a high risk medical device that currently appears on the FDA watch list. We have been working with this company to research known use problems, re-write their risk assessment, […]

Prefilled syringe conference (Europe) 2017 – Day 2

21st January 2017

Just when I thought it couldn’t get better, day 2 turned out to be just that. I presented some brand new research (our own research, NOT for a client) that investigated what patients want from their injection devices. Its no exaggeration to say that it went down extremely well with delegates. I got question after […]

Prefilled Syringe conference (Europe) 2017 – Day 1

19th January 2017

First day ends at the Prefilled Syringe conference in London, and usability was right at centre stage. Virtually every talk included a reference to usability. First up was a senior regulator from the MHRA, who referred everyone to their new human factors guidance and devoted three slides to talking about how important usability was. He […]

Combination products discussion at PFS Europe 2017 conference

11th January 2017

It has just been confirmed that Richard Featherstone will be taking part in the panel discussion at the PFS Europe conference on Wednesday 18th January at 4.40pm. The title of the discussion is “Combination products – challenges and opportunities”. The discussion will be moderated by Alphons Fakler of Novartis and the other panellists are David […]